Peter P Huang

US Patent:

8626863, Jan 7, 2014

Filed:

Oct 28, 2008

Appl. No.:

12/259902

Inventors:

Peter Chi-Hao Huang - Menlo Park CA, US
Erin Turner - San Francisco CA, US

Assignee:

Trion Worlds, Inc. - Redwood City CA

International Classification:

G06F 15/16

US Classification:

709207, 709206

Abstract:

Persistent synthetic environment message notification is described, including retrieving synthetic environmental data associated with an event occurring within a synthetic environment, identifying one or more formats to configure the synthetic environmental data and to transmit the synthetic environmental data, generating a message comprising the synthetic environmental data, the message being generated based on at least one of the one or more formats, and sending the message comprising the synthetic environmental data to an endpoint.

US Patent:

20100229107, Sep 9, 2010

Filed:

Mar 6, 2009

Appl. No.:

12/399902

Inventors:

Erin E. Turner - San Francisco CA, US
Peter Chi-Hao Huang - Menlo Park CA, US

Assignee:

Trion World Networks, Inc. - Redwood city CA

International Classification:

G06F 3/048
G06F 15/16

US Classification:

715757, 709246, 709206

Abstract:

Cross-interface communication is described, including generating data associated with a synthetic environment, the synthetic environment comprising one or more communication protocols, converting the data using one of the one or more communication protocols to generate converted data, wherein the converted data is interpreted using another of the one or more communication protocols, and transmitting the data over a communication path between two or more endpoints using one or more communication interfaces, wherein the data, after being interpreted by the another of the one or more communication protocols, is used to present information associated with the synthetic environment on at least one of the two or more endpoints.

US Patent:

20220324775, Oct 13, 2022

Filed:

Aug 12, 2020

Appl. No.:

17/634879

Inventors:

- San Diego CA, US
Joseph Robert Pinchman - San Diego CA, US
Peter Qinhua Huang - San Diego CA, US
Kevin Duane Bunker - Escondido CA, US

International Classification:

C07C 1/28

Abstract:

Processes of making [1.1.1]propellane utilize reaction conditions that include reacting 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane with an effective amount of solid magnesium.

US Patent:

20220273666, Sep 1, 2022

Filed:

Jul 8, 2020

Appl. No.:

17/597471

Inventors:

- San Diego CA, US
Aditya Krishnan Unni - San Diego CA, US
Yosef Shamay - San Diego CA, US
Kevin Duane Bunker - Escondido CA, US
Peter Qinhua Huang - San Diego CA, US

International Classification:

A61K 31/5377
A61K 31/496
A61K 9/51
A61K 47/64

Abstract:

Various albumin nanoparticle Bcl-2 inhibitor formulations are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments, such Bcl-2 inhibitor formulations contain albumin and a compound of the following Formula (I), or a pharmaceutically acceptable salt thereof, where the variables in Formula (I) are defined herein.

US Patent:

20220265834, Aug 25, 2022

Filed:

Jul 8, 2020

Appl. No.:

17/597474

Inventors:

- San Diego CA, US
Kevin Duane Bunker - Escondido CA, US
Peter Qinhua Huang - San Diego CA, US

International Classification:

A61K 47/55
A61K 47/54
A61P 35/00

Abstract:

Various Bcl-2 protein inhibitors are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments the Bcl-2 protein inhibitors are compounds or pharmaceutically acceptable salts of the following Formula (I), where the variables in Formula (I) are defined herein.

US Patent:

20220235050, Jul 28, 2022

Filed:

Apr 4, 2022

Appl. No.:

17/657841

Inventors:

- San Diego CA, US
Peter Qinhua Huang - San Diego CA, US
Kevin Duane Bunker - Escondido CA, US
Sayee Gajanan Hegde - San Diego CA, US

International Classification:

C07D 471/04
A61P 35/00

Abstract:

Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.

US Patent:

20220226314, Jul 21, 2022

Filed:

Mar 28, 2022

Appl. No.:

17/656726

Inventors:

- San Diego CA, US
Peter Qinhua Huang - San Diego CA, US
Kevin Duane Bunker - Escondido CA, US
Rakesh Kumar Sit - San Diego CA, US
Ahmed Abdi Samatar - San Diego CA, US

International Classification:

A61K 31/496
A61K 31/5355
A61K 45/06
C07D 413/12
C07D 471/04
C07D 519/00
C07D 241/04
C07D 205/04
C07D 207/12
C07D 211/46
C07D 211/58
C07D 295/112
C07D 295/13

Abstract:

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.

US Patent:

20230087941, Mar 23, 2023

Filed:

Dec 16, 2020

Appl. No.:

17/757486

Inventors:

- San Diego CA, US
Jiali Li - San Diego CA, US
Jianhui Ma - San Diego CA, US
Peter Qinhua Huang - San Diego CA, US
Sayee Gajanan Hegde - San Diego CA, US
Brant Clayton Boren - San Diego CA, US
Kevin Duane Bunker - Escondido CA, US
Fernando Donate - Santa Monica CA, US

International Classification:

A61K 31/437
A61K 31/519
A61K 45/06
A61P 35/00

Abstract:

Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.